Roivant Sciences (NASDAQ:ROIV) Shares Down 6.4% – Time to Sell?

Posted by George Bondi on Aug 28th, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report)’s stock price dropped 6.4% during trading on Friday . The stock traded as low as $35.17 and last traded at $35.17. 1,707,108 shares changed hands during trading, a decline of 71% from the average session volume of 5,890,813 shares. The stock had previously closed at $37.58.

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

Positive Sentiment: The FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis, a rare inflammatory disease affecting the skin and muscles. The once-daily oral treatment is described as the first targeted therapy—and first oral drug—for the condition, giving Roivant and partner Priovant a potentially differentiated product in an underserved market. Reuters FDA approval article
Positive Sentiment: LISRAYA is now available in the United States, allowing Roivant and Priovant to begin generating commercial revenue rather than relying solely on pipeline milestones. The launch price is $35,000 for a 30-day supply, supporting the possibility of substantial revenue per treated patient, subject to insurance coverage, patient access and adoption. Reuters LISRAYA launch pricing article
Positive Sentiment: HC Wainwright reaffirmed its Buy rating and set a $41 price target, implying roughly 14.7% upside from the cited $35.76 reference price. The endorsement may reinforce investor confidence in LISRAYA’s commercial opportunity. HC Wainwright analyst rating
Neutral Sentiment: The approval removes a significant regulatory risk, but investors will likely focus next on prescription volume, reimbursement, launch costs and how economics are shared with Priovant and Pfizer. Roivant remains unprofitable, so commercial execution will be important to justify its valuation.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ROIV. Citigroup increased their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday. Leerink Partners set a $42.00 price objective on Roivant Sciences in a report on Thursday, May 21st. Finally, Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Get Our Latest Stock Report on Roivant Sciences

Roivant Sciences Trading Down 5.0%

The firm has a market capitalization of $25.79 billion, a P/E ratio of -67.38 and a beta of 1.12. The company’s fifty day simple moving average is $35.09 and its 200 day simple moving average is $30.88.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. On average, analysts predict that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Insider Activity at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $56,376,551.85. This represents a 11.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the transaction, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. The trade was a 51.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,855,913 shares of company stock valued at $100,107,258. 8.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently made changes to their positions in ROIV. VELA Investment Management LLC purchased a new stake in Roivant Sciences in the second quarter worth $207,000. Corient Private Wealth LP lifted its position in Roivant Sciences by 48.7% during the second quarter. Corient Private Wealth LP now owns 12,666 shares of the company’s stock valued at $448,000 after buying an additional 4,148 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Roivant Sciences during the second quarter valued at $2,166,000. California State Teachers Retirement System lifted its position in Roivant Sciences by 4,212.2% during the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock valued at $672,448,000 after buying an additional 18,560,434 shares during the period. Finally, HB Wealth Management LLC boosted its holdings in shares of Roivant Sciences by 5.1% during the 2nd quarter. HB Wealth Management LLC now owns 11,062 shares of the company’s stock valued at $391,000 after buying an additional 537 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.